Incyte and Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial focus on collaboration targets selected...

View the Online Magazine

Launches

Ultra-Hygienic mixing at small-scale

Introducing the new 150 UHS Ultra-Hygienic Small-Scale In-Line mixer from Silverson Machines. The 150 UHS In-Line is designed for Ultra Hygienic applications typically encountered in...

Pioneer Group drives AI innovation in healthcare through industry and academic collaboration

Pioneer Group, the life science infrastructure and venture building specialist, has joined forces with Innovate UK, The Medical Research Council (MRC) and AstraZeneca, to...

New SWLP laboratory at Croydon Hospital transforms the diagnostic facility into one of the most advanced and innovative in the UK

South West London Pathology (SWLP) introduces cutting-edge technologies to its laboratories to create one of the most modern, innovative, and efficient clinical blood science...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Pharmanovia signs exclusive distribution agreement with Er-Kim for Sunosi in Eastern Europe

Pharmanovia has signed an exclusive distribution agreement with Er-Kim, to enhance the availability of Sunosi (Solriamfetol), a first-in-class treatment for Excessive Daytime Sleepiness (EDS),...

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15, a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S. and Europe

Dr. Reddy’s Laboratories has entered into a license agreement with Shanghai Henlius Biotech for the commercialization of HLX15, Henlius’ investigational daratumumab biosimilar candidate to...

Er-Kim signs distribution agreement with the MEDICE Health Family for Vafseo in Central & Eastern Europe

Er-Kim, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, has signed a distribution agreement with the MEDICE...

Er-Kim extends exclusive distribution agreement with Ascendis to expand commercialization of endocrinology portfolio

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, has extended its exclusive agreement with Danish biopharmaceutical company Ascendis Pharma to commercialize...

Approvals

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment...

Mirum’s CTEXLI tablets receives FDA approval for cerebrotendinous xanthomatosis

The U.S. Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals' CTEXLI (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous...

Manufacturiung

Finance

Research & Development
Latest

Incyte and Genesis Therapeutics enter strategic collaboration focused on novel small molecule medicines

Incyte and Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines, with an initial...

Infex signs exclusive license agreement with Venus Remedies to advance MET-X through clinical development and commercialisation in India

Infex Therapeutics, an anti-infectives specialist, has signed an exclusive license agreement for the Indian market with Venus Remedies, an Indian pharmaceutical company, for the...

U.S. FDA grants Breakthrough Therapy Designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Innate Pharma's lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment...

AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies

AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...

Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...

Appointments